PAVmed (PAVM) Q2 FY26 earnings call

PAVmed reported tangible progress across its core businesses in Q2 FY26, with Lucid advancing reimbursement and Veris building commercial momentum while developing its implantable device. The relaunched medical device portfolio, including PortIO and Octaris, is also moving forward, with PortIO showing promising first-in-human results and exploring a faster regulatory pathway. The company remains committed to its diversified model, aiming to enhance shareholder value through multiple opportunities despite increased R&D spend and a modest cash balance.